In summary, over the past 10 years by far the most amazing benefit has become achieved in HER2/neu-overexpressing MBC. Introduction of bevacizumab like a VEGF-directed qualified treatment remains a difficulty on discussion. A lot of the novel therapeutics into the breast cancer armamentarium resulted in prolongation of survival for patients with MB